The epidemiology of antibiotic-resistant clinical pathogens in Uganda.


Journal

Journal of global health
ISSN: 2047-2986
Titre abrégé: J Glob Health
Pays: Scotland
ID NLM: 101578780

Informations de publication

Date de publication:
30 Aug 2024
Historique:
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 30 8 2024
Statut: epublish

Résumé

Antibiotic resistance (ABR) is a global challenge, and its control depends on robust evidence primarily derived from surveillance systems. We utilised a national surveillance data set to demonstrate how such evidence can be systematically generated. In doing so, we characterised the ABR profiles of priority clinical pathogens, identified associated factors, and drew inferences on antibiotic usage in Uganda. Of the 12 262 samples collected between 2019-21, we analysed 9033 with complete metadata. ABR was steadily increasing at a rate of 0.5% per year, with a surge in 2021 and the highest and lowest levels of penicillin and carbapenems detected in the northern (odds ratio (OR) = 2.26; P < 0.001) and the northeast (OR = 0.28; P < 0.001) regions of Uganda respectively. ABR was commonly observed with Escherichia coli (OR = 1.18; P < 0.001) and Klebsiella pneumoniae (OR = 1.25; P < 0.001) among older and male patients (61-70 years old) (OR = 1.88; P = 0.005). Multi-drug resistance (MDR) and ABR were disproportionately higher among bloodstream infections than respiratory tract infections and urinary tract infections, often caused by Acinetobacter baumannii. Co-occurrence of ABR suggests that cephalosporins such as ceftriaxone are in high use all over Uganda. ABR is indeed a silent pandemic, and our results suggest it is increasing at 0.5% per year, with a notable surge in 2021 likely due to coronavirus disease 2019 (COVID-19). Of concern, ABR and MDR are mainly associated with bloodstream and surgical wound infections, with a gender and age dimension. However, it is encouraging that carbapenem resistance remains relatively low. Such evidence is critical for contextualising the implementation and evaluation of national action plans.

Sections du résumé

Background UNASSIGNED
Antibiotic resistance (ABR) is a global challenge, and its control depends on robust evidence primarily derived from surveillance systems.
Methods UNASSIGNED
We utilised a national surveillance data set to demonstrate how such evidence can be systematically generated. In doing so, we characterised the ABR profiles of priority clinical pathogens, identified associated factors, and drew inferences on antibiotic usage in Uganda.
Results UNASSIGNED
Of the 12 262 samples collected between 2019-21, we analysed 9033 with complete metadata. ABR was steadily increasing at a rate of 0.5% per year, with a surge in 2021 and the highest and lowest levels of penicillin and carbapenems detected in the northern (odds ratio (OR) = 2.26; P < 0.001) and the northeast (OR = 0.28; P < 0.001) regions of Uganda respectively. ABR was commonly observed with Escherichia coli (OR = 1.18; P < 0.001) and Klebsiella pneumoniae (OR = 1.25; P < 0.001) among older and male patients (61-70 years old) (OR = 1.88; P = 0.005). Multi-drug resistance (MDR) and ABR were disproportionately higher among bloodstream infections than respiratory tract infections and urinary tract infections, often caused by Acinetobacter baumannii. Co-occurrence of ABR suggests that cephalosporins such as ceftriaxone are in high use all over Uganda.
Conclusions UNASSIGNED
ABR is indeed a silent pandemic, and our results suggest it is increasing at 0.5% per year, with a notable surge in 2021 likely due to coronavirus disease 2019 (COVID-19). Of concern, ABR and MDR are mainly associated with bloodstream and surgical wound infections, with a gender and age dimension. However, it is encouraging that carbapenem resistance remains relatively low. Such evidence is critical for contextualising the implementation and evaluation of national action plans.

Identifiants

pubmed: 39212655
doi: 10.7189/jogh.14.04184
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

04184

Informations de copyright

Copyright © 2024 by the Journal of Global Health. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and disclose no relevant interests.

Auteurs

Ritah Namusoosa (R)

Department of National Health Laboratories and Diagnostic Services, National Microbiology Reference Laboratory, Ministry of Health, Kampala, Uganda.

Ibrahim Mugerwa (I)

Department of National Health Laboratories and Diagnostic Services, Ministry of Health, Kampala, Uganda.

Keneth Iceland Kasozi (KI)

Infection Medicine, College of Medicine and Veterinary Medicine, Deanery of Biomedical Sciences, The University of Edinburgh, Edinburgh, UK.
School of Medicine, Kabale University, Kabale, Uganda.

Allan Muruta (A)

Department of National Disease Control, Ministry of Health, Kampala, Uganda.

Grace Najjuka (G)

Department of National Health Laboratories and Diagnostic Services, National Microbiology Reference Laboratory, Ministry of Health, Kampala, Uganda.

Winifred D Atuhaire (WD)

Department of National Health Laboratories and Diagnostic Services, National Microbiology Reference Laboratory, Ministry of Health, Kampala, Uganda.

Susan Nabadda (S)

Department of National Health Laboratories and Diagnostic Services, Ministry of Health, Kampala, Uganda.

Henry Mwebesa (H)

Directorate of Curative Services, Ministry of Health, Kampala, Uganda.

Charles Olaro (C)

Directorate of Curative Services, Ministry of Health, Kampala, Uganda.

Isaac Ssewanyana (I)

Department of National Health Laboratories and Diagnostic Services, Ministry of Health, Kampala, Uganda.

Aloysious Ssemaganda (A)

Department of National Health Laboratories and Diagnostic Services, Ministry of Health, Kampala, Uganda.

Adrian Muwonge (A)

The Digital One Health Laboratory, Division of Epidemiology, Roslin Institute, The University of Edinburgh, Edinburgh, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH